Presentations from the 2nd Annual Advances in Men’s Health
These lectures were presented during the 2nd Annual Advances in Men’s Health in August 2022, in Big Sky, Montana.
Read MoreFeatured Content
ADT Side Effects: Cardiovascular Disease
In a program supported by Verity Pharmaceuticals, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego, discusses reinforcing consistent testosterone suppression in ADT and the role of triptorelin with Scott B. Sellinger, MD, President of Advanced Urology Institute and a Partner at Southeastern Urological Center in Tallahassee, Florida, and Paul R. Sieber, MD, FACS, President of Keystone Urology Specialists in Lancaster, Pennsylvania.
Read MorePresentations from the 32nd Annual International Prostate Cancer Update
These lectures were presented during the 32nd Annual International Prostate Cancer Update in March 2022, in Snowbird, Utah.
Read More
ADT as Foundational Therapy, and the Need for Consensus on Consistent T Suppression, Goals, Monitoring, and Delaying Time to CRPC
In a program supported by Verity Pharmaceuticals, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego; Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center; and Benjamin H. Lowentritt, MD, FACS, Director of Prostate Cancer Services for United Urology Group discuss androgen deprivation therapy (ADT) as a foundational therapy for prostate cancer. They discuss managing testosterone (T) levels, adherence to T dosing schedules, and castrate-resistant prostate cancer (CRPC).
Read More
Reinforcing Consistent Testosterone Suppression in ADT
E. David Crawford, MD, Scott B. Sellinger, MD, and Paul R. Sieber, MD, discuss reinforcing consistent testosterone suppression in ADT and the role of triptorelin.
Read More